Creatv Bio, a division of Creatv MicroTech, Inc., has officially opened a full-service, CLIA-certified laboratory in Monmouth Junction, significantly expanding New Jersey’s footprint in the specialized field of liquid biopsy and cancer diagnostics.
The state-of-the-art facility is designed to support biopharmaceutical companies in accelerating oncology drug development and clinical trial testing. By utilizing the company’s proprietary LifeTracDx® Blood Test, the lab provides a non-invasive way to monitor how patients respond to new therapies in real time.
The Monmouth Junction lab will focus on measuring Cancer Associated Macrophage-Like cells (CAMLs) and Circulating Tumor Cells (CTCs). CAMLs are a critical biomarker that can be detected in nearly all types of malignancies.
Crucially for drug developers, these cells can predict a patient’s response to treatment within just 30 to 45 days of drug administration—far earlier than traditional clinical endpoints like tumor shrinkage on a scan.
The opening of the CLIA-certified facility allows Creatv Bio to offer several high-tech services to pharmaceutical partners:
-
Early response monitoring: Assessing drug efficacy weeks or months ahead of standard methods.
-
Precision patient selection: Helping trial sponsors identify and exclude patients unlikely to respond to a specific intervention, saving time and resources.
-
Real-time biomarker tracking: Monitoring drug target expression and potential resistance through simple blood draws rather than invasive tissue biopsies.
-
Immunotherapy support: The lab offers a unique blood test for detecting PD-L1 expression changes, a vital metric for patients using checkpoint inhibitors.
The selection of Monmouth Junction for this facility reinforces Central Jersey’s reputation as a premier hub for life sciences and biotech innovation.
“The opening of our CLIA Laboratory now enables us to offer a fully equipped facility to deliver rapid, reliable analyses to our pharmaceutical partners,” Dr. Cha-Mei Tang, president and CEO of Creatv Bio said. “This is a major step forward in accelerating cancer drug development.”
While the LifeTracDx® test is currently intended for research and investigational use, its application in translational studies is expected to play a major role in how the next generation of cancer treatments is developed and refined.
